Why Genetic Testing Claims Get Denied — and How Labs Prevent Them (2026 Guide)

ScreenMyGene Team·Published August 26, 2026·9 min read·Clinically reviewed by Dr. Ashraf, Ph.D.
Lab revenue-cycle specialist reviewing denied genetic testing insurance claims

Short answer: Genetic-testing claims fail for a small number of predictable, preventable reasons: no prior authorization on file, a diagnosis code that does not establish medical necessity, an indication the payer's coverage policy does not list, a missing MolDX DEX Z-Code, a duplicate of a once-in-a-lifetime test, or documentation that never made it into the chart. Denial rates for cancer-related advanced genetic testing climbed from 16.8% before 2018 to 27.4% after 2020, and claims from independent laboratories are nearly twice as likely to be denied as the same tests billed by hospital labs. The economics are unforgiving — but nearly every one of these failure modes is visible before the sample is run. Labs that check eligibility, coding, and coverage upstream prevent denials instead of appealing them.

The denial problem, by the numbers

A Georgetown University analysis of commercial claims found that denial rates for cancer-related advanced genetic testing rose from 16.8% (pre-2018) to 27.4% (post-2020) — more than one in four claims. The same analysis found claims for NGS testing performed in independent laboratories were denied at nearly twice the rate of hospital-based testing. Each denied claim triggers rework: an appeal with a letter of medical necessity, a resubmission with corrected codes, or a write-off. For high-cost panels, a persistent 25%+ denial rate is not a billing nuisance — it is a structural threat to a lab's revenue integrity.

The six reasons genetic testing claims get denied

1. No prior authorization on file

Most commercial payers and Medicare Advantage plans require prior authorization for high-cost genetic tests. When testing proceeds without an approved PA — or the PA covers a different CPT code than the one billed — the claim is denied administratively before medical necessity is even considered. Prevention is procedural: confirm PA requirements per payer and per test before the specimen is accessioned, and make sure the authorized codes match what will actually be billed.

2. The diagnosis code doesn't establish medical necessity

The single most preventable denial. The ICD-10-CM code on the claim is the payer's evidence that the test was medically needed. A vague encounter code such as Z01.89, a screening code where a diagnostic indication exists, or a code that simply is not on the policy's covered list will sink an otherwise legitimate claim. The chart usually contains a specific, codable indication — a personal history code (Z85.x), a family-history code (Z80.x), or a documented condition — but it never makes it onto the claim. Our companion guide to ICD-10 codes for genetic testing covers the code families that support medical necessity, and the ones that quietly cause denials.

3. The indication isn't covered by the payer's policy

Coverage for genetic testing is policy-specific and, for Medicare, often geography-specific. A test may be covered nationally under an NCD (for example, NGS in certain cancers under NCD 90.2), covered locally under a MAC's LCD, or not covered at all for the documented indication. Ordering against the wrong policy — or assuming national coverage where only a local determination exists — produces a denial that no coding correction can fix. The mechanics are laid out in our guide to Medicare coverage for genetic testing: LCD, NCD & MolDX.

4. Missing or wrong MolDX DEX Z-Code

In MolDX jurisdictions, a single CPT code can describe many different molecular tests, so claims must carry the DEX Z-Code that identifies exactly which test was performed. A molecular claim without the correct Z-Code is typically denied on receipt. This is a lab-side registration and claims-configuration issue — entirely preventable, and entirely invisible until the remittance arrives.

5. Duplicate of a once-in-a-lifetime test

Medicare's NGS coverage rules generally prohibit re-billing the same germline NGS test for the same cancer for the same beneficiary. If prior testing isn't verified at intake, the lab runs a test that was never payable. Verification of prior equivalent testing — and documented justification when a re-order is legitimate — belongs at the front of the workflow, not in the appeal letter.

6. The documentation never made it into the record

Payers deny what they cannot see. The clinician may have taken a three-generation family history in the room, but if the chart says "family history of cancer" with no specifics, the claim's supporting documentation is thin, the PA is weak, and the appeal has nothing to stand on. Medical-necessity documentation — the indication, the specific findings, and the code that matches them — has to exist in the record before the order goes out.

How labs prevent denials: move the checks upstream

Every failure mode above is detectable before a sample is processed. Prevention looks like this:

Doing this manually for every order is exactly the workload that overwhelms lab client-services and revenue-integrity teams. It is also the reconciliation ScreenMyGene automates: it reads the chart, surfaces the panels the patient actually qualifies for, and anchors each recommendation to a documented, matching diagnosis code and the applicable coverage policy — so the order is defensible before submission, not corrected after denial.

Frequently asked questions

Why are genetic tests denied by insurance?
Most denials trace to six causes: missing prior authorization, a diagnosis code that fails to establish medical necessity, an indication outside the payer's coverage policy, a missing MolDX Z-Code, duplication of a once-in-a-lifetime test, or insufficient documentation in the record.

What percentage of genetic testing claims are denied?
Published analysis of commercial claims found denial rates for cancer-related advanced genetic testing rose from 16.8% before 2018 to 27.4% after 2020, with independent laboratories denied at nearly twice the rate of hospital labs.

What ICD-10 codes support genetic testing claims?
Codes that document a specific covered indication: personal-history codes (Z85.x), family-history codes (Z80.x, Z84.81), genetic-susceptibility codes (Z15.0x), carrier-status codes (Z14.x), and specific disease codes. Vague encounter codes like Z01.89 are a leading denial cause.

How can labs reduce genetic testing denials?
Shift verification upstream: confirm PA and prior testing at intake, anchor each order to a documented matching ICD-10-CM code, reconcile against the governing NCD/LCD or payer policy, and confirm DEX Z-Code configuration before claims go out.

Do denied genetic testing claims get overturned on appeal?
Many do, particularly with a strong letter of medical necessity — but appeals recover revenue at high administrative cost and weeks of delay. Preventing the denial upstream is cheaper than winning it back.

Educational disclaimer: This article summarizes claims and coverage concepts as of 2026 for general information. Payer policies, NCDs, LCDs, and MolDX requirements change and vary by contractor and plan. This is not billing, legal, or medical advice; verify against current CMS and payer policy with qualified billing professionals. ScreenMyGene is clinical decision support and does not replace independent professional judgment.

Sources: Georgetown University School of Health analysis of denial rates for cancer-related advanced genetic testing; CMS Medicare Coverage Database (NCD 90.2; Billing & Coding articles A58918, A58801); Palmetto GBA MolDX / DEX Diagnostics Exchange registry documentation.